Mabpharm (HKSE:02181) COGS-to-Revenue : 0.13 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Mabpharm COGS-to-Revenue?

Mabpharm's Cost of Goods Sold for the six months ended in Dec. 2023 was HK$6.26 Mil. Its Revenue for the six months ended in Dec. 2023 was HK$47.19 Mil.

Mabpharm's COGS to Revenue for the six months ended in Dec. 2023 was 0.13.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Mabpharm's Gross Margin % for the six months ended in Dec. 2023 was 86.73%.

Mabpharm COGS-to-Revenue Historical Data

The historical data trend for Mabpharm's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mabpharm COGS-to-Revenue Chart

Mabpharm Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.20

0.27

0.14

Mabpharm Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial								-	0.38	0.16	0.14	0.13

Mabpharm COGS-to-Revenue Calculation

Mabpharm's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	13.041	/	95.335
	=	0.14

Mabpharm's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	6.262	/	47.187
	=	0.13

Mabpharm (HKSE:02181) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Mabpharm's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	6.262 / 47.187
	=	86.73 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Mabpharm COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Mabpharm's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Mabpharm (HKSE:02181) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabpharm Ltd (HKSE:02181) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Lujia Road East, Koutai Road West, Block G79, China Medical City, Taizhou, CHN, 225300

Website

http://www.mabpharm.cn

Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab).

Executives

Guo Jianjun	2307 Founder of a discretionary trust who can infl
Asia Mabtech Limited
Asia Pacific Immunotech Venture Limited
Guo Family (ptc) Limited
Fortune-healthy Investment Limited
Link Best Capital Limited
Cdh Fund V, L.p.
Cdh Mabtech Limited
Cdh V Holdings Company Limited
China Diamond Holdings Company Limited
China Diamond Holdings V Limited

Mabpharm (HKSE:02181) Headlines

No Headlines